Oral semaglutide was associated with improved survival outcomes in patients with heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, extending injectable semaglutide HFpEF benefits to oral formulation.
Pill saves heartsOral semaglutide's HFpEF survival benefit extends injectable semaglutide's heart failure protection to a convenient daily pill form
What the researchers found
Oral semaglutide: improved survival in HFpEF + T2D patients, extending injectable semaglutide's heart failure benefits to oral formulation.
Why it matters
HFpEF is the most common heart failure type with few treatments. An oral drug improving survival could transform HFpEF care.
How the study worked
Study of oral semaglutide effects on survival outcomes in HFpEF + T2D patients.
What this study cannot tell us
Details in full paper. Oral semaglutide bioavailability is lower than injectable.
How to read the evidence
Study of oral semaglutide in HFpEF.
When this study was published
Published in 2025.
The bigger picture
Oral semaglutide achieving HFpEF benefits means heart failure treatment can be as simple as taking a daily pill.
Questions still open
- Does oral semaglutide HFpEF benefit match injectable?
- Should oral semaglutide be first-line for HFpEF+T2D?
- Would higher oral doses provide greater benefit?
Common questions
Can an oral pill treat heart failure?
Is the pill as good as the injection for heart failure?
Read the original research
Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.
Diabetes, obesity & metabolism, 28(3), 2374-2382
Citation
Kishimori, Takefumi; Kato, Takao; Iwasaki, Yoshihiro; Shimada, Takenobu; Wada, Atsuyuki; Tani, Akira; Yamaji, Ryosuke; Koike, Jumpei; Matsumoto, Takehiro; Yagi, Takafumi; Okada, Masaharu. (2026). Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes.. Diabetes, obesity & metabolism, 28(3), 2374-2382. https://doi.org/10.1111/dom.70433